newwin
Luciann Nguyen
Settings
← Accounts
academic

Institute of Cancer Research, United Kingdom

47
Account opportunity
Not established
Relationship
1
Active signals
1
Trials as sponsor

Why this account matters

Institute of Cancer Research, United Kingdom

New trial — POTENT - Tepotinib in Combination With Pembrolizumab in NSCLC

New trialNCT05782361
47/100
Opportunity
Commercial fit6/25
Clinical timing19/20
Biomarker need5/20
Relationship2/10
Signal strength9/10
Account value5/10
Urgency1/5

New phase 1 trial NCT05782361 posted by Institute of Cancer Research, United Kingdom: "POTENT - Tepotinib in Combination With Pembrolizumab in NSCLC". New trial on a phase 1 active not recruiting study is a moment when external vendors are commonly selected or expanded (spec §70).

Why nowClinicalTrials.gov record updated 137 days ago.

ConfidenceHigh · 87%clinical development · translational medicine · clinical operations
Draft outreachReview

NextHold. Score is below the tenant threshold (55). Keep on the watchlist for follow-on signals.

Trials

TrialPhaseTesting language
NCT05782361
POTENT - Tepotinib in Combination With Pembrolizumab in NSCLC
phase 1
ctDNA